Similar Prognosis of Patients with Bone-only Metastatic Breast Cancer and Visceral Metastasis

Background: Bone-only metastatic breast cancer is believed to be non-lifethreatening,and mild therapy is frequently selected to avoid adverse events of drugtherapy. However, the prognoses of such patients are not well studied.Methods: Patients who received drug therapies for metastatic breast cancerbetween 2004 and 2016 at our institution were divided into the “Bone-onlymetastasis”, “non-visceral”, and “visceral” groups based on the mode of the firstmetastasis, and the efficacy of the first-line therapy and survival of these patientswere compared.Results: There were 131 eligible patients, and the bone-only metastasis, nonvisceral,and visceral groups included 26, 25, and 80 patients, respectively. Themedian survival time (MST) of the overall survival (OS) in each group was 35.1,34.9, and 37.4 months, respectively (p=0.71). The clinical benefit rates of first-linetherapy in the bone-only metastasis, non-visceral, and visceral groups were 66.7%,45%, and 69.3%, respectively, and the MST of the time to treatment failure (TTF)in each group was 6.3, 5.5, and 5.8 months, respectively, showing that the efficacyof first-line therapy did not significantly differ among the groups. In the bone-onlymetastasis group, patients with <5 metastases tended to have a good prognosis, andthose with a low nuclear grade and long first-line therapy duration had asignificantly better prognosis than others.Conclusion: The patients with bone-only metastasis had a similar prognosisand treatment response to those with other modes of metastasis, and the patientswith a good response to the first-line therapy had a good prognosis.

Similar Prognosis of Patients with Bone-only Metastatic Breast Cancer and Visceral Metastasis Keywords:

Secondary breast neoplasms , bone metastasis , prognosis